NASDAQ · CELU
Healthcare · Biotechnology
$1.71
Down-$0.15 (-8.77%)
Updated Oct 6, 2026, 7:18 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CELU
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CELU closed at $1.71 after 20 trading sessions, up 11.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.60 | $1.80 | $1.57 | $1.71 | 282.13K |
| Oct 2, 2026 | $1.37 | $1.635 | $1.36 | $1.60 | 221.84K |
| Oct 1, 2026 | $1.34 | $1.38 | $1.302 | $1.38 | 142.15K |
| Sep 30, 2026 | $1.37 | $1.37 | $1.28 | $1.35 | 55.43K |
| Sep 29, 2026 | $1.38 | $1.3999 | $1.3343 | $1.37 | 39.65K |
| Sep 28, 2026 | $1.40 | $1.46 | $1.35 | $1.40 | 113.62K |
| Sep 25, 2026 | $1.33 | $1.41 | $1.32 | $1.38 | 166.07K |
| Sep 24, 2026 | $1.17 | $1.35 | $1.17 | $1.32 | 454.72K |
| Sep 23, 2026 | $1.17 | $1.18 | $1.13 | $1.15 | 77.12K |
| Sep 22, 2026 | $1.22 | $1.26 | $1.16 | $1.18 | 154.73K |
| Sep 21, 2026 | $1.27 | $1.33 | $1.24 | $1.24 | 214.04K |
| Sep 18, 2026 | $1.28 | $1.35 | $1.22 | $1.31 | 188.4K |
| Sep 17, 2026 | $1.29 | $1.38 | $1.27 | $1.27 | 77.76K |
| Sep 16, 2026 | $1.26 | $1.3891 | $1.21 | $1.29 | 181.1K |
| Sep 15, 2026 | $1.33 | $1.40 | $1.24 | $1.24 | 149.41K |
| Sep 14, 2026 | $1.32 | $1.43 | $1.31 | $1.40 | 206.97K |
| Sep 11, 2026 | $1.45 | $1.45 | $1.351 | $1.41 | 97.11K |
| Sep 10, 2026 | $1.405 | $1.48 | $1.3848 | $1.435 | 158.55K |
| Sep 9, 2026 | $1.55 | $1.55 | $1.43 | $1.44 | 148.75K |
| Sep 8, 2026 | $1.70 | $1.734 | $1.52 | $1.54 | 249.67K |
The latest Smart Investors Daily articles mentioning CELU.
Company
Market Activity
Research & News
CELU research
Company profile and research snapshot.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2025 | WBB Securities | Buy | — |
| Aug 18, 2025 | WBB Securities | Speculative Buy | — |
| Jan 30, 2023 | Morgan Stanley | Underweight | — |
| Jan 30, 2023 | HC Wainwright & Co. | Buy | — |
| Dec 22, 2022 | Oppenheimer | Perform | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
Celularity (NASDAQ:CELU) reported quarterly earnings of $0.02 per share. This is a 102.38 percent increase over losses of $(0.84) per share from the same period last year. The company reported $3.846 million in sales
Yahoo · Sep 29, 2026
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive healthFLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors. Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is
Yahoo · Sep 24, 2026
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion Company anticipates positive monthly operating cash flow by the end of Q1 2027 Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company,
Benzinga · Sep 24, 2026
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansionCompany anticipates positive monthly operating cash flow by the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CELU.
